Conavi Medical to Highlight Novasight Hybrid™ Imaging at TCT 2025
Conavi Medical (OTCQB: CNVIF) will highlight its Novasight Hybrid™ intravascular imaging at TCT 2025 in San Francisco, Oct 25–28, 2025, with booth #2126.
The company will present clinical images from its first‑generation IVUS/OCT system and participate in physician‑led Intravascular Imaging & Training sessions on Oct 26–27. Conavi said the next‑generation Novasight Hybrid was submitted for FDA 510(k) clearance in September 2025. The first‑generation system previously received FDA 510(k) clearance, Health Canada approval, and was used at seven luminary cardiovascular hospitals in North America.
Conavi Medical (OTCQB: CNVIF) will highlight its Novasight Hybrid™ intravascular imaging at TCT 2025 in San Francisco, Oct 25–28, 2025, with booth #2126.
L'azienda presenterà immagini cliniche dal suo sistema di prima generazione IVUS/OCT e parteciperà a sessioni di Imaging Intravascular & Training guidate dai medici il 26–27 ottobre. Conavi ha dichiarato che la prossima generazione di Novasight Hybrid è stata inviata per l'autorizzazione FDA 510(k) nel settembre 2025. Il sistema di prima generazione aveva già ottenuto l'autorizzazione FDA 510(k), l'approvazione Health Canada ed è stato utilizzato in sette ospedali cardiovascolari di riferimento in Nord America.
Conavi Medical (OTCQB: CNVIF) destacará su imagenología intravascular Novasight Hybrid™ en TCT 2025 en San Francisco, del 25 al 28 de octubre de 2025, con el stand #2126.
La empresa presentará imágenes clínicas de su sistema de primera generación IVUS/OCT y participará en sesiones de Intravascular Imaging & Training dirigidas por médicos los 26–27 de octubre. Conavi dijo que la próxima generación de Novasight Hybrid fue presentada para la aprobación FDA 510(k) en septiembre de 2025. El sistema de primera generación ya recibió la aprobación FDA 510(k), la aprobación de Health Canada, y fue utilizado en siete hospitales cardiovasculares de referencia en Norteamérica.
Conavi Medical (OTCQB: CNVIF)은 샌프란시스코에서 열리는 TCT 2025에서 Novasight Hybrid™ 혈관내 영상화 기술을 하이라이트하며, 2025년 10월 25일–28일, 부스 #2126에서 개최됩니다.
회사는 1세대 IVUS/OCT 시스템의 임상 이미지를 제시하고 10월 26–27일에 의사 주도의 혈관내 영상 및 교육 세션에 참여할 예정입니다. 콘아비는 차세대 Novasight Hybrid가 2025년 9월에 FDA 510(k) 승인을 위한 제출되었다고 밝혔습니다. 1세대 시스템은 이미 FDA 510(k) 승인, Health Canada 승인을 받았으며 북미의 일곱 개의 핵심 심혈관 병원에서 사용되었습니다.
Conavi Medical (OTCQB: CNVIF) mettra en lumière son imagerie intravasculaire Novasight Hybrid™ lors du TCT 2025 à San Francisco, du 25 au 28 octobre 2025, au stand #2126.
L'entreprise présentera des images cliniques de son système IVUS/OCT de première génération et participera à des sessions d'Imagerie Intravasculaire & Formation dirigées par des médecins les 26–27 octobre. Conavi a indiqué que la prochaine génération du Novasight Hybrid a été soumise pour une autorisations FDA 510(k) en septembre 2025. Le système de première génération avait déjà obtenu une autorisation FDA 510(k), une approbation Health Canada et a été utilisé dans sept hôpitaux cardiovasculaires de référence en Amérique du Nord.
Conavi Medical (OTCQB: CNVIF) wird seine Novasight Hybrid™ intravaskuläre Bildgebung auf der TCT 2025 in San Francisco vom 25. bis 28. Oktober 2025 mit dem Stand #2126 hervorheben.
Das Unternehmen wird klinische Bilder aus seinem ersten Generation IVUS/OCT-System präsentieren und an ärztlich geführten Intravascular Imaging & Training-Sitzungen am 26.–27. Oktober teilnehmen. Conavi erklärte, dass der nächste Generationsschritt des Novasight Hybrid im September 2025 zur FDA 510(k)-Freigabe eingereicht wurde. Das Erstgenerationssystem hatte zuvor eine FDA 510(k)-Freigabe, eine Health-Canada-Zulassung erhalten und wurde in sieben führenden Herz-Kreislauf-Krankenhäusern in Nordamerika eingesetzt.
Conavi Medical (OTCQB: CNVIF) ستسلط الضوء على تصويرها داخل الأوعية الدموية Novasight Hybrid™ في TCT 2025 في سان فرانسيسكو، من 25 إلى 28 أكتوبر 2025، مع الجناح #2126.
ستقدم الشركة صوراً سريرية من نظام IVUS/OCT من الجيل الأول وتشارك في جلسات التصوير داخل الأوعية الدموية والتدريب التي يقودها الأطباء في 26–27 أكتوبر. قالت Conavi إن الجيل التالي من Novasight Hybrid قد تم تقديمه للحصول على تصريح FDA 510(k) في سبتمبر 2025. لقد حصل نظام الجيل الأول سابقاً على تصريح FDA 510(k)، و< b>موافقة Health Canada، وتم استخدامه في سبعة مستشفيات قلبية رائدة في أمريكا الشمالية.
Conavi Medical (OTCQB: CNVIF) 将在 TCT 2025 于旧金山于 2025 年 10 月 25–28 日的展位 #2126，突出其 Novasight Hybrid™ 血管内成像。
该公司将展示其第一代 IVUS/OCT 系统的临床图像，并于 10 月 26–27 日 参加由医生主导的血管内成像与培训课程。Conavi 表示，下一代 Novasight Hybrid 已于 2025 年 9 月提交 FDA 510(k) 审批。第一代系统此前已经获得 FDA 510(k) 审批、Health Canada 批准，并在北美的 七家知名心血管医院 使用。
- None.
- None.
Company to Participate in Educational Imaging Sessions and Feature Hybrid IVUS/OCT Imaging Technology
TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a commercial-stage medical device company focused on intravascular imaging solutions, today announced that it will participate in the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference, taking place October 25 – 28, 2025, at the Moscone Center in San Francisco, California.
Attendees will have the opportunity to learn more about Conavi’s hybrid intravascular imaging technology, which combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to provide complementary insights into coronary anatomy. Conavi will share clinical images acquired using its first-generation Novasight Hybrid™ imaging system and provide information on the potential role of hybrid IVUS/OCT imaging in guiding complex percutaneous coronary interventions (PCI).
“TCT provides an important forum for clinical education and scientific exchange in interventional cardiology,” said Thomas Looby, President and CEO of Conavi Medical. “We look forward to engaging with physicians and thought leaders to discuss how hybrid intravascular imaging can enhance procedural decision-making and improve patient outcomes.”
The next-generation version of Conavi’s Novasight Hybrid system was submitted to the U.S. Food and Drug Administration (FDA) for 510(k) clearance in September 2025. Conavi’s first-generation version previously received FDA 510(k) clearance and Health Canada approval and was used at seven luminary cardiovascular care hospitals in North America.
Intravascular Imaging Education Sessions
Conavi will also participate in the Intravascular Imaging & Training sessions at the Imaging & Training Center, held throughout the day on Sunday, October 26, and Monday, October 27.
These physician-led sessions will feature expert case presentations illustrating how intravascular imaging can be used to guide challenging PCI procedures, including those involving calcified lesions, acute coronary syndrome (ACS), and in-stent restenosis (ISR).
Conference Details
- Event: Transcatheter Cardiovascular Therapeutics (TCT) 2025
- Dates: October 26 – 29, 2025
- Location: Moscone Center, San Francisco, California
- Conavi Medical Booth: #2126
About TCT
The Transcatheter Cardiovascular Therapeutics (TCT) conference, organized by the Cardiovascular Research Foundation (CRF), is the world’s leading educational meeting specializing in interventional cardiovascular medicine. TCT brings together thousands of physicians, scientists, and industry leaders from around the globe to present the latest research, live cases, and innovations in device-based therapies for coronary, structural, and endovascular disease.
About Conavi Medical
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid™ System received regulatory clearance in the U.S., Canada, China, and Japan. For more information, visit conavi.com.
Cautionary Statement Regarding Forward-Looking Information
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to Conavi’s plans for the commercialization of its Novasight Hybrid™ System and expected FDA clearance and the commercial launch of next generation Novasight in the U.S.
These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi’s ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the “Risk Factors” sections of the joint information circular of Conavi dated August 30, 2024 and in the final short form prospectus of Conavi dated April 15, 2025 (each of which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Contact:
Stefano Picone
Chief Financial Officer
(416) 483-0100
FAQ
When and where will Conavi Medical present Novasight Hybrid at TCT 2025?
What regulatory progress did Conavi announce for the Novasight Hybrid (CNVIF)?
What clinical content will Conavi share at TCT 2025 about Novasight Hybrid (CNVIF)?
How widely has Conavi’s first‑generation Novasight Hybrid been used in North America?
Which TCT sessions will feature Conavi’s intravascular imaging demonstrations?
